Lisata Therapeutics Engages in Key September Investor Events
BASKING RIDGE, N.J. — Lisata Therapeutics, Inc. (NASDAQ: LSTA) is pleased to announce its participation in several important industry events this September. This is a vital opportunity for the company, which is dedicated to developing groundbreaking therapies for advanced solid tumors and other serious conditions.
Participation in Annual Global Investment Conference
Lisata will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9 to 11, 2024. The conference will be held in a virtual format, allowing a wide audience to access the presentations. Lisata’s session will be available on-demand starting September 9. Dr. David J. Mazzo, the President and Chief Executive Officer of Lisata, will lead the presentation, where he will discuss the company’s innovative strategies and advancements in clinical therapies.
Presence at the LSX World Congress USA
Following the global investment conference, Lisata will take part in the 2024 LSX World Congress USA on September 11-12, 2024. Unlike the previous virtual event, this congress will be held in person at the Hynes Convention Center in Boston. On September 12, Dr. Mazzo will present at 11:15 a.m. Eastern Time, sharing insights into Lisata’s recent developments and future objectives.
About Lisata Therapeutics
Lisata Therapeutics is leading the way in clinical-stage pharmaceutical development. The company is committed to creating transformative therapies, particularly targeting advanced solid tumors. Its main product candidate, certepetide, is an investigational drug that has attracted considerable interest. This drug aims to enhance the targeting and penetration of solid tumors by utilizing a novel uptake pathway, potentially transforming cancer treatment.
Innovative Partnerships and Future Milestones
Lisata has formed impressive commercial and research partnerships that capitalize on its proprietary CendR Platform technology. The company is on track to reach several significant milestones in the coming years, supported by projected capital that will fund operations into early 2026. These developments include expected data releases from ongoing clinical trials, which are likely to provide new insights into oncology.
Investor Relations Contacts
For inquiries about investment opportunities, please contact:
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media Relations
For media-related inquiries, please reach out to:
ICR Westwicke
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
Frequently Asked Questions
What is Lisata Therapeutics focused on?
Lisata Therapeutics is committed to developing innovative therapies for advanced solid tumors and other serious diseases.
Who will present at the H.C. Wainwright conference?
Dr. David J. Mazzo, the President and CEO of Lisata, will be the main presenter at the conference.
When is the 2024 LSX World Congress USA taking place?
The LSX World Congress USA is scheduled for September 11 to 12, 2024, at the Hynes Convention Center in Boston.
What is certepetide?
Certepetide is an investigational drug from Lisata designed to enhance the effectiveness of anti-cancer therapies by more effectively targeting solid tumors.
How can I contact Lisata Therapeutics?
You can contact Lisata Therapeutics through the investor relations or media relations representatives listed above.